Delcath Systems Inc
Symbol: DCTH (NASDAQ)
Company Description:
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
- Today's Open: $11.2
- Today's High: $11.35
- Today's Low: $10.819
- Today's Volume: 176.99K
- Yesterday Close: $11.13
- Yesterday High: $11.3272
- Yesterday Low: $11.07
- Yesterday Volume: 415.23K
- Last Min Volume: 806
- Last Min High: $10.855
- Last Min Low: $10.819
- Last Min VWAP: $10.83654
- Name: Delcath Systems Inc
- Website: https://www.delcath.com
- Listed Date: 2000-10-19
- Location: QUEENSBURY, NY
- Market Status: Active
- CIK Number: 0000872912
- SIC Code: 3841
- SIC description: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
- Market Cap: $388.99M
- Round Lot: 100
- Outstanding Shares: 34.98M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-08-15 | S-8 | View |
2025-08-15 | 8-K | View |
2025-08-06 | 10-Q | View |
2025-08-06 | 8-K | View |
2025-06-13 | 4 | View |
2025-05-22 | 8-K | View |
2025-05-19 | 4 | View |
2025-05-19 | 4 | View |
2025-05-19 | 4 | View |
2025-05-19 | 4 | View |
2025-05-19 | 4 | View |
2025-05-16 | 8-K | View |
2025-05-15 | SCHEDULE 13G/A | View |
2025-05-12 | SCHEDULE 13D/A | View |
2025-05-09 | 4 | View |
2025-05-09 | 4 | View |
2025-05-09 | 4 | View |
2025-05-08 | 10-Q | View |
2025-05-08 | 8-K | View |
2025-04-01 | ARS | View |